The Medical Letter on Drugs and Therapeutics
Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ticagrelor (Brilinta – AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use.1 Clopidogrel is expected to become available generically in the US within the next few months.

STANDARD TREATMENT — Aspirin plus clopidogrel or prasugrel is the standard of care for antiplatelet therapy in patients with ACS (unstable angina [UA], non-ST elevation myocardial infarction [NSTEMI], acute MI [STEMI] or percutaneous coronary intervention [PCI]).

Clopidogrel is a prodrug that requires conversion to an active form; genetic polymorphisms and some other drugs may interfere with its activation.2,3 The antiplatelet ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?
Article code: 1372a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian